BackIncyte Overview
Incyte Corp.

Incyte Target Price

Analysts' average 12-month price target for Incyte is $120.

Get informed when a big investor buys or sells

+ Follow

Share Price

$126.75

Average Target Price

$123.172.8% downside

23 analysts in the last 4 months

High: $155 | Low: $94

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-20Canaccord Genuity$15219.9% upsideOpen
2026-08-17Piper SandlerAllison Bratzel$1302.6% upsideOpen
2026-08-13Bernstein$10417.9% downsideOpen
2026-08-03Leerink PartnersAndrew Berens$15522.3% upsideOpen
2026-07-29RBC CapitalBrian Abrahams$10914% downsideOpen
2026-07-29BMO Capital$1302.6% upsideOpen
2026-07-29GuggenheimWhitney Ljem$15018.3% upsideOpen
2026-07-29Morgan Stanley$1196.1% downsideOpen
2026-07-29H.C. Wainwright$15018.3% upsideOpen
2026-07-29Barclays$1399.7% upsideOpen
2026-07-28Stifel NicolausStephen Willey$14514.4% upsideOpen
2026-07-28Oppenheimer$1205.3% downsideOpen
2026-07-23Morgan Stanley$10417.9% downsideOpen
2026-07-14Barclays$1345.7% upsideOpen
2026-07-13BMO Capital$11211.6% downsideOpen
2026-07-07RBC Capital$9921.9% downsideOpen
2026-06-26UBS$11310.8% downsideOpen
2026-06-22Truist Financial$10517.2% downsideOpen
2026-06-22BMO CapitalEvan David Seigerman$9425.8% downsideOpen
2026-06-10H.C. WainwrightMitchell Kapoor$14010.5% upsideOpen
2026-06-09Stifel NicolausStephen Willey$1233% downsideOpen
2026-06-08OppenheimerJay Olson$10715.6% downsideOpen
2026-05-21Bernstein$9921.9% downsideOpen
2026-04-29Oppenheimer$9029% downsideOpen
2026-02-18Barclays$1177.7% downsideOpen
2026-02-11Morgan Stanley$10219.5% downsideOpen
2026-02-11Stifel NicolausStephen Willey$1205.3% downsideOpen
2026-02-06Piper SandlerAllison Bratzel$11013.2% downsideOpen
2026-02-05H.C. Wainwright$1356.5% upsideOpen
2026-02-04Barclays$1168.5% downsideOpen
2026-01-20Wells Fargo$10715.6% downsideOpen
2026-01-08Goldman Sachs$9029% downsideOpen
2026-01-05Stifel NicolausStephen Willey$1196.1% downsideOpen
2025-12-24Truist FinancialSrikripa Devarakonda$10318.7% downsideOpen
2025-12-08Morgan Stanley$9227.4% downsideOpen
2025-12-08Wells FargoDerek Archila$1168.5% downsideOpen
2025-12-08Mizuho SecuritiesSalim Syed$1214.5% downsideOpen
2025-11-24Barclays$1159.3% downsideOpen
2025-11-04Piper SandlerAllison Bratzel$10219.5% downsideOpen
2025-10-29Truist Financial$9326.6% downsideOpen
2025-10-29RBC Capital$8433.7% downsideOpen
2025-10-29Wells FargoDerek Archila$9723.5% downsideOpen
2025-10-29BarclaysPeter Lawson$10120.3% downsideOpen
2025-07-30UBS$6846.4% downsideOpen
2025-06-23RBC Capital$6747.1% downsideOpen
2025-03-18Guggenheim$9227.4% downsideOpen
2024-10-30Seaport GlobalAaron Kessler$20057.8% upsideOpen
2024-10-30OppenheimerJay Olson$8235.3% downsideOpen
2024-10-30CitigroupDavid Lebowitz$9723.5% downsideOpen
2024-10-29JefferiesKelly Shi$8433.7% downsideOpen

Incyte (INCY) FAQ

Incyte posts a target price of $120. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $120 for INCY means covering analysts, on average, see the stock 2.8% downside of $126.75 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for INCY's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Incyte's other metric pages and overview cover the third.

Judging Incyte against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $120 here, then scan peer and history charts to see if the gap is persistent.